CVRx Announces Increased Inpatient Payment for Barostim Procedure
02 Agosto 2024 - 7:00AM
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical
device company, announced today that Centers for Medicare and
Medicaid Services (CMS) has reassigned the Barostim implant
procedure for the inpatient setting as part of the Fiscal Year (FY)
2025 Medicare Hospital Inpatient Prospective Payment System (IPPS)
final rule.
In FY 2024, Barostim was assigned to MS-DRGs 252, 253, 254 with
a national average payment range of $17,000-$23,000. For FY 2025,
Barostim will be reassigned to MS-DRG 276, which carries a national
average payment of approximately $43,000. The new payment takes
effect Oct. 1, 2024.
“We applaud CMS’ consideration and recognition of the resource
requirements associated with the Barostim implant procedure. We
believe that reassignment to MS-DRG 276 will facilitate increased
access to the therapy for patients with heart failure by
establishing sufficient reimbursement for the procedure when
performed in an inpatient setting,” said Kevin Hykes, President and
CEO of CVRx.
About CVRx, Inc. CVRx is focused on the
development and commercialization of the Barostim™ System, the
first medical technology approved by FDA that uses neuromodulation
to improve the symptoms of heart failure. Barostim is an
implantable device that delivers electrical pulses to baroreceptors
located in the wall of the carotid artery. Baroreceptors activate
the body’s baroreflex, which in turn triggers an autonomic response
to the heart. The therapy is designed to restore balance to the
autonomic nervous system and thereby reduce the symptoms of heart
failure. Barostim received the FDA Breakthrough Device designation
and is FDA-approved for use in heart failure patients in the U.S.
It has also received the CE Mark for heart failure and resistant
hypertension in the European Economic Area. To learn more about
Barostim, visit www.cvrx.com.
Media Contact:
Laura O’Neill Finn Partners 917.497.2867
laura.oneill@finnpartners.com
Investor Contact:
Mark Klausner or Mike Vallie ICR Westwicke 443.213.0501
ir@cvrx.com
CVRx (NASDAQ:CVRX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
CVRx (NASDAQ:CVRX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024